Definium Therapeutics shares surged as much as 60% after late-stage trial data showed "groundbreaking" results for its experimental psychedelic treatment for major depressive disorders. The news materially improves the company's clinical profile and investor sentiment, though the impact is primarily stock-specific rather than sector-wide.
Definium Therapeutics shares surged as much as 60% after late-stage trial data showed "groundbreaking" results for its experimental psychedelic treatment for major depressive disorders. The news materially improves the company's clinical profile and investor sentiment, though the impact is primarily stock-specific rather than sector-wide.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.82
